Hemostatic and thrombotic parameters in acure leukemia- A comparison of pre and post remission induction phase
DOI:
https://doi.org/10.38106/LMRJ.2022.4.2-03Keywords:
Hemostasis, Thrombotic markers , Fibrinolysis, pre and post induction chemotherapy, LeukemiaAbstract
This study was aimed to compare hemostatic, fibrinolytic and thrombotic parameters in pre and post induction chemotherapy in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). A total of 110 diagnosed acute leukemia patients and 40 normal individuals were enrolled in the study. Questionnaire were filled and patients’ blood specimens were collected before the commencement and post induction chemotherapy. Prothrombin time (PT), activated partial thromboplastin time (aPTT), von Willebrand factor antigen (vWF Ag), fibrinogen level, factor VIIIc (FVIIIc), D-Dimers, fibrinogen degradation products (FDPs), anti-thrombin III (AT), lupus anticoagulant (LA), protein C (PC), protein S and diluted russel viper venom test (DRVVT) were conducted in all the participants. A significant rise was identified in post-induction levels of PT, aPTT, vWF Ag, fibrinogen and factor VIII in acute leukemia patients. Analysis of fibrinolytic markers indicated increased D-Dimers and plasminogen levels while the levels of alpha 2 anti-plasmin were reduced in pretreated patients. Thrombotic markers’ assessment showed increased levels of AT and LA while decreased level of PC in pretreated acute leukemia patients. It was concluded that remission induction chemotherapy, in acute leukemia patients, significantly affects the coagulation, fibrinolytic and thrombotic parameters.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Tehmina Nafees Sonia Khan, Tariq Masood, Zara tul ain Bashir, Tasneem Farzana, Abdul Sattar, Tahir Shamsi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: Open access journal copyright lies with authors and protected under CC BY-NC-ND 4.0 licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).